See more : EF-ON Inc. (9514.T) Income Statement Analysis – Financial Results
Complete financial analysis of Bio-Path Holdings, Inc. (BPTH) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Bio-Path Holdings, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- ESM Acquisition Corporation (ESM-WT) Income Statement Analysis – Financial Results
- China Holdings, Inc. (CHHL) Income Statement Analysis – Financial Results
- Lovable Marketing Group,inc. (9254.T) Income Statement Analysis – Financial Results
- CGN Nuclear Technology Development Co., Ltd. (000881.SZ) Income Statement Analysis – Financial Results
- Toscana Aeroporti S.p.A. (TYA.MI) Income Statement Analysis – Financial Results
Bio-Path Holdings, Inc. (BPTH)
About Bio-Path Holdings, Inc.
Bio-Path Holdings, Inc. operates as a clinical and preclinical stage oncology focused RNAi nano particle drug development company in the United States. The company develops products based on DNAbilize, a drug delivery and antisense technology that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification intended to protect the DNA from destruction. Its lead drug candidate is prexigebersen, which is in Phase II clinical trials for the treatment of acute myeloid leukemia (AML) and myelodysplastic syndrome. It is also developing Liposomal Bcl-2 for the treatment of refractory/relapsed lymphoma and chronic lymphocytic leukemia; Liposomal STAT3 that is in preclinical stage for the treatment of pancreatic cancer, non-small cell lung cancer, and AML; and prexigebersen-A for various solid tumors. Bio-Path Holdings, Inc. was founded in 2007 and is based in Bellaire, Texas.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 37.00K | 13.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 18.44K | 43.81K | 59.45K | 79.31K |
| Cost of Revenue | 178.00K | 178.00K | 161.00K | 151.00K | 230.00K | 426.00K | 0.00 | 0.00 | 201.76K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 20.11K | 37.77K | 43.88K | 55.42K |
| Gross Profit | -178.00K | -178.00K | -161.00K | -151.00K | -230.00K | -426.00K | 37.00K | 13.00K | -201.76K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -1.67K | 6.05K | 15.58K | 23.90K |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 100.00% | 100.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -9.05% | 13.80% | 26.20% | 30.13% |
| Research & Development | 11.61M | 9.17M | 5.91M | 6.58M | 4.59M | 4.60M | 5.48M | 5.47M | 3.02M | 1.83M | 1.63M | 1.60M | 1.14M | 1.14M | 480.26K | 333.47K | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 4.11M | 4.74M | 4.53M | 4.33M | 4.11M | 3.38M | 3.52M | 3.01M | 2.46M | 2.72M | 1.63M | 986.10K | 0.00 | 704.88K | 1.31M | 587.16K | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 123.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 4.24M | 4.74M | 4.53M | 4.33M | 4.11M | 3.38M | 3.52M | 3.01M | 2.46M | 2.72M | 1.63M | 986.10K | 1.22M | 704.88K | 1.31M | 587.16K | 107.44K | 141.31K | 82.53K | 78.16K |
| Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 608.00K | 0.00 | 0.00 | 196.66K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 182.98K | 171.95K | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 15.84M | 13.90M | 10.44M | 10.91M | 8.69M | 7.98M | 9.00M | 8.49M | 5.48M | 4.54M | 3.27M | 2.58M | 2.37M | 1.85M | 1.97M | 1.09M | 107.44K | 141.31K | 82.53K | 78.16K |
| Cost & Expenses | 15.84M | 13.90M | 10.44M | 10.91M | 8.69M | 7.98M | 9.00M | 8.49M | 5.48M | 4.54M | 3.27M | 2.58M | 2.37M | 1.85M | 1.97M | 1.09M | 127.55K | 179.08K | 126.40K | 133.58K |
| Interest Income | 36.00K | 33.00K | 3.00K | 26.00K | 94.00K | 7.00K | 9.00K | 12.00K | 17.67K | 22.63K | 4.04K | 779.00 | 2.91K | 1.30K | 3.38K | 41.06K | 0.00 | 541.00 | 132.00 | 1.35K |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 15.94K | 13.08K | 17.62K | 13.26K |
| Depreciation & Amortization | 82.00K | 178.00K | 161.00K | 151.00K | 230.00K | 426.00K | 411.00K | 204.00K | 201.76K | 170.91K | 160.63K | 185.27K | 211.71K | 197.27K | 182.98K | 171.95K | 1.68K | 2.72K | 3.03K | 3.06K |
| EBITDA | -15.76M | -13.69M | -10.28M | -10.73M | -8.37M | -8.16M | -8.56M | -8.27M | -5.27M | -4.35M | -3.11M | -2.40M | -2.15M | -1.88M | -1.79M | -2.68M | -107.44K | -132.00K | -63.79K | -49.85K |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -28,348.65% | -76,800.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -973.44% | -301.30% | -107.30% | -62.85% |
| Operating Income | -15.84M | -13.90M | -10.44M | -10.91M | -8.69M | -8.59M | -8.97M | -8.48M | -5.48M | -4.54M | -3.27M | -2.58M | -2.37M | -2.33M | -1.97M | -2.89M | -109.11K | -135.27K | -66.95K | -54.26K |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -24,232.43% | -65,192.31% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -591.78% | -308.75% | -112.61% | -68.42% |
| Total Other Income/Expenses | -235.00K | 33.00K | 3.00K | 26.00K | 94.00K | 7.00K | 1.94M | 1.73M | 18.21K | 22.05K | 3.23K | -344.86K | 2.27K | -232.43K | 3.38K | 41.06K | 56.67K | -12.54K | -17.49K | -11.91K |
| Income Before Tax | -16.08M | -13.87M | -10.44M | -10.88M | -8.60M | -8.58M | -7.02M | -6.75M | -5.47M | -4.52M | -3.27M | -2.58M | -2.36M | -2.08M | -1.97M | -2.85M | -52.45K | -147.81K | -84.44K | -66.17K |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -18,981.08% | -51,923.08% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -284.44% | -337.37% | -142.02% | -83.43% |
| Income Tax Expense | 0.00 | -33.00K | -3.00K | -26.00K | -94.00K | -608.00K | -1.94M | -1.73M | 0.00 | -22.30K | -3.23K | -142.00 | -2.27K | 232.43K | 0.00 | 2.85M | 100.00 | 100.00 | 100.00 | 100.00 |
| Net Income | -16.08M | -13.84M | -10.44M | -10.86M | -8.51M | -8.58M | -7.02M | -6.75M | -5.47M | -4.52M | -3.27M | -2.58M | -2.36M | -2.08M | -1.97M | -2.85M | -52.55K | -147.91K | -84.54K | -66.27K |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -18,981.08% | -51,923.08% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -284.99% | -337.60% | -142.19% | -83.56% |
| EPS | -33.64 | -38.03 | -31.04 | -56.44 | -64.02 | -287.54 | -278.69 | -291.26 | -243.61 | -202.50 | -183.04 | -174.15 | -175.57 | -172.91 | -186.06 | -277.22 | -3.84 | -14.13 | -13.71 | -10.75 |
| EPS Diluted | -33.64 | -38.03 | -31.04 | -56.44 | -64.02 | -287.54 | -278.69 | -291.26 | -243.61 | -202.50 | -183.04 | -174.15 | -175.57 | -172.91 | -186.06 | -277.22 | -3.84 | -14.13 | -13.71 | -10.75 |
| Weighted Avg Shares Out | 478.00K | 363.80K | 336.25K | 192.35K | 132.85K | 29.85K | 25.20K | 23.18K | 22.44K | 22.32K | 17.84K | 14.83K | 13.46K | 12.04K | 10.59K | 10.29K | 13.69K | 10.47K | 6.17K | 6.17K |
| Weighted Avg Shares Out (Dil) | 478.00K | 363.80K | 336.25K | 192.35K | 132.85K | 29.85K | 25.20K | 23.18K | 22.44K | 22.32K | 17.84K | 14.83K | 13.46K | 12.04K | 10.59K | 10.29K | 13.69K | 10.47K | 6.17K | 6.17K |
Bio-Path Holdings Announces Successful Completion of First Dose Cohort in Phase 1/1b Clinical Trial of BP1001-A in Solid Tumors
Advancing to Second Cohort of Phase 1/1b Clinical Trial Evaluating BP1001-A to Treat Patients with Solid Tumors, Including Ovarian, Endometrial, Pancreatic and Breast Cancer Advancing to Second Cohort of Phase 1/1b Clinical Trial Evaluating BP1001-A to Treat Patients with Solid...
Why Is Bio-Path (BPTH) Stock Down 12% Today?
Bio-Path (NASDAQ: BPTH ) stock is sliding lower on Monday after the company announced a proposed public share offering. Bio-Path has yet to reveal the major details of its planned public offering.
Bio-Path Holdings, Inc. (BPTH) Q1 2023 Earnings Call Transcript
Bio-Path Holdings, Inc. (NASDAQ:BPTH ) Q1 2023 Earnings Conference Call May 12, 2023 8:30 AM ET Company Participants Will O'Connor - Investor Relations, Stern IR Peter Nielsen - President and Chief Executive Officer Anthony Price - Senior Vice President of...
Bio-Path Holdings to Announce First Quarter 2023 Financial Results on May 12, 2023
HOUSTON, May 05, 2023 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ: BPTH) a biotechnology company leveraging its proprietary DNAbilize® antisense RNAi nanoparticle technology to develop a portfolio of targeted nucleic acid cancer drugs, today announced that it will host a...
Bio-Path Holdings to Announce Fourth Quarter and Full Year 2022 Financial Results on March 31, 2023
HOUSTON, March 24, 2023 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc. (NASDAQ: BPTH), a biotechnology company leveraging its proprietary DNAbilize® antisense RNAi nanoparticle technology to develop a portfolio of targeted nucleic acid cancer drugs, today announced that it will host a...
Bio-Path Holdings Inc. (BPTH) Q3 2022 Earnings Call Transcript
Bio-Path Holdings Inc. (NASDAQ:BPTH ) Q3 2022 Earnings Conference Call November 15, 2022 8:30 AM ET Company Participants Will O'Connor - Stern Investor Relations Peter Nielsen - CEO and CFO Anthony Price - SVP of Finance, Accounting and Administration Conference...
Bio-Path Holdings to Announce Third Quarter 2022 Financial Results on November 15, 2022
HOUSTON, Nov. 08, 2022 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ: BPTH) a biotechnology company leveraging its proprietary DNAbilize® antisense RNAi nanoparticle technology to develop a portfolio of targeted nucleic acid cancer drugs, today announced that it will host a...
Bio-Path Holdings to Present at H.C. Wainwright 24th Annual Global Investment Conference
HOUSTON, Sept. 06, 2022 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ: BPTH) a biotechnology company leveraging its proprietary DNAbilize® antisense RNAi nanoparticle technology to develop a portfolio of targeted nucleic acid cancer drugs, today announced that Peter Nielsen, Chief Executive...
Bio-Path Holdings Inc.'s (BPTH) CEO Peter Nielsen on Q2 2022 Results - Earnings Call Transcript
Bio-Path Holdings, Inc. (NASDAQ:BPTH ) Q2 2022 Earnings Conference Call August 16, 2022 8:30 AM ET Company Participants Will O'Connor - Stern Investor Relations Peter Nielsen - CEO and CFO Anthony Price - SVP of Finance, Accounting and Administration Conference...
Bio-Path Holdings to Announce Second Quarter 2022 Financial Results on August 16, 2022
HOUSTON, Aug. 09, 2022 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ: BPTH) a biotechnology company leveraging its proprietary DNAbilize® antisense RNAi nanoparticle technology to develop a portfolio of targeted nucleic acid cancer drugs, today announced that it will host a...
Source: https://incomestatements.info
Category: Stock Reports